About Pharming Group NV (OTCMKTS:PHGUF)
Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company’s products are aimed at treatments for genetic disorders and surgical and traumatic bleeding. Pharming’s technologies include novel transgenic platforms for the production of biopharmaceuticals, as well as technology and processes for the purification and formulation of these biopharmaceuticals. The Company’s commercial partners are: Santarus, Sobi, MegaPharm, Eczacibasi, Transmedic and Hyupjin. The Company operates worldwide. In March 2014, it announced downsizing of the Dutch operations following from strategic re-emphasis on collaborative development efforts and out-sourcing of non-core activities.
Industry, Sector and Symbol:
- Industry: N/A
- Sub-Industry: N/A
- Sector: Medical
- Symbol: OTCMKTS:PHGUF
- Previous Symbol: OTC:PHGUF
- CUSIP: N/A
- Web: www.pharming.com
- Debt-to-Equity Ratio: 11.72%
- Current Ratio: 1.77%
- Quick Ratio: 1.27%
Sales & Book Value:
- Annual Sales: $17.57 million
- Price / Sales: 45.71
- Book Value: $0.07 per share
- Price / Book: 21.43
- Net Income: ($19,400,000.00)
- Net Margins: -69.48%
- Return on Equity: -215.48%
- Return on Assets: -35.22%
- Employees: 94
- Outstanding Shares: 535,360,000
Frequently Asked Questions for Pharming Group NV (OTCMKTS:PHGUF)
What is Pharming Group NV's stock symbol?
Pharming Group NV trades on the OTCMKTS under the ticker symbol "PHGUF."
How were Pharming Group NV's earnings last quarter?
Pharming Group NV (OTCMKTS:PHGUF) issued its earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.04 by $0.01. Pharming Group NV had a negative net margin of 69.48% and a negative return on equity of 215.48%. View Pharming Group NV's Earnings History.
When will Pharming Group NV make its next earnings announcement?
Who are some of Pharming Group NV's key competitors?
Some companies that are related to Pharming Group NV include Integer Holdings Corporation (ITGR), William Demant Holdings (WILYY), Ablynx Nv (ABLYF), Innoviva (INVA), Phibro Animal Health Corporation (PAHC), MyoKardia (MYOK), HMS Holdings Corp (HMSY), BAVARIAN NORDIC (BVNRY), Zogenix (ZGNX), Impax Laboratories (IPXL), LHC Group (LHCG), Irhythm Tech (IRTC), Momenta Pharmaceuticals (MNTA), Genomic Health (GHDX), Ignyta (RXDX), Luminex Corporation (LMNX), Orthofix International N.V. (OFIX) and Pharmerica Corporation (PMC).
Who are Pharming Group NV's key executives?
Pharming Group NV's management team includes the folowing people:
- Paul Jai Sekhri, Chairman of the Board of Supervisory Directors (Age 59)
- Sijmen de Vries, Member of the Management Board, Chief Executive Officer (Age 58)
- Juergen H. L. Ernst, Vice Chairman of the Board of Supervisory Directors (Age 78)
- Robin Wright, Chief Financial Officer, Member of the Management Board (Age 53)
- Bruno M. Giannetti, Member of the Management Board, Chief Operations Officer (Age 65)
- Anne-Marie de Groot, Senior Vice President Organizational Development, Member of the Management Board
- Jaap Blaak, Member of the Board of Supervisory Directors (Age 76)
- Aad de Winter, Member of the Board of Supervisory Directors (Age 64)
- Jan H. Egberts M.D., Member of the Board of Supervisory Directors (Age 58)
- Jonh Barrie Ward Ph.D., Member of the Board of Supervisory Directors (Age 76)
How do I buy Pharming Group NV stock?
Shares of Pharming Group NV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pharming Group NV's stock price today?
One share of Pharming Group NV stock can currently be purchased for approximately $1.50.
How big of a company is Pharming Group NV?
Pharming Group NV has a market capitalization of $765.56 million and generates $17.57 million in revenue each year. Pharming Group NV employs 94 workers across the globe.
How can I contact Pharming Group NV?
MarketBeat Community Rating for Pharming Group NV (OTCMKTS PHGUF)MarketBeat's community ratings are surveys of what our community members think about Pharming Group NV and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pharming Group NV's mailing address is Darwinweg 24, LEIDEN, 2333 CR, Netherlands. The biotechnology company can be reached via phone at +31-71-5247400 or via email at [email protected]
Analysts' Consensus Ratings for Pharming Group NV (OTCMKTS:PHGUF) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Analysts' Consensus Price Target: ||N/A|Consensus Price Target History for Pharming Group NV (OTCMKTS:PHGUF)
Analysts' Ratings History for Pharming Group NV (OTCMKTS:PHGUF)
(Data available from 11/17/2015 forward)
|10/26/2017||HC Wainwright||Reiterated Rating||Buy|
|1/24/2017||Roth Capital||Reiterated Rating||Buy|
Earnings History for Pharming Group NV (OTCMKTS:PHGUF)Earnings History by Quarter for Pharming Group NV (OTCMKTS PHGUF)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/8/2018|| || || || || || || || |
Earnings Estimates for Pharming Group NV (OTCMKTS:PHGUF)
Current Year EPS Consensus Estimate: $-0.07 EPS
Next Year EPS Consensus Estimate: $0.07 EPS
Dividend History for Pharming Group NV (OTCMKTS:PHGUF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Pharming Group NV (OTCMKTS PHGUF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Pharming Group NV (OTCMKTS:PHGUF)
Latest Headlines for Pharming Group NV (OTCMKTS PHGUF)
No headlines for this company have been tracked by MarketBeat.com
Financials are not available for this stock.
Pharming Group NV (OTCMKTS PHGUF) Chart for Friday, November, 17, 2017